Goldman Sachs published a research report, listing the latest investment ratings and Target Prices for China's Medical health stocks as follows:
Stock | Investment Rating | Target Price (HKD)
HANSOH PHARMA (03692.HK) | Buy | 20.97 yuan -> 21.51 yuan
SINO BIOPHARM (01177.HK) | Buy | 4.1 yuan -> 3.96 yuan
CSPC PHARMA (01093.HK) | Buy | 8.52 yuan
FOSUN PHARMA (02196.HK) | Neutral | 18.18 yuan -> 16.83 yuan
LIVZON PHARMA (01513.HK) | Neutral | 22.58 yuan -> 21.1 yuan
3SBIO (01530.HK) | Neutral | 8.16 yuan -> 9.02 yuan
UNITED LAB (03933.HK) | Neutral | Target Price 10.25 yuan -> 10.5 yuan
HEPALINK (09989.HK) | Sell | Target Price 3.76 yuan -> 3.47 yuan
SINOPHARM (01099.HK) | Neutral | Target Price 18.97 yuan -> 20.32 yuan
SH PHARMA (02607.HK) | Sell | Target Price 12.87 yuan -> 12.1 yuan
CHINARES PHARMA (03320.HK) | Neutral | Target Price 6.11 yuan -> 6.04 yuan
Comment(0)
Reason For Report